Darwin L. Cheney, Ph.D.
The Nano Institute of Utah
Associate Director, Nano Institute of Utah; President & CEO, TheraTarget, Inc.
383 Colorow Dr Rm 311 Salt Lake City, UT 84108
Dr. Cheney joined Utah Science, Technology and Research (USTAR) initiative in April, 2008 as Director for the Utah Initiative for Nanotechnology and Applications working with USTAR Professors at the University of Utah to commercialize their scientific technologies. In that capacity he incorporated three companies and was instrumental in gaining approval for the Nano Institute of Utah. He has since transferred to the University of Utah as Associate Director of the Nano Institute of Utah. He previously served as President and CEO of FIDIA Research Foundation and as professor of Pharmacology at Georgetown University in Washington, D.C. Dr. Cheney has special expertise in business development, research and development process optimization, performance management, and strategic and operational improvements. Prior to coming to Utah Dr. Cheney spent three years in Macclesfield, England, as Chief Scientific Officer of Cyprotex Discovery.
Dr. Cheney has a broad background in pharmaceutical research and development having served as Director of Neuroscience and Cardiovascular Discovery in the Research Department and later as Executive Director of Clinical Operations and Statistics in the Development Department of CIBA-GEIGY Pharmaceutical company (now Novartis) He has spent the past fifteen years in contract research working with small companies to achieve and expand profitability.
Dr. Cheney obtained his BS in Zoology and his MS in Physiology at Brigham Young University. He received his Ph.D. in Pharmacology from Stanford University. His research interests are focused on the pharmacodynamic effects of psychotropic drugs on neurotransmitter turnover in selected brain areas. Dr. Cheney has 116 publications.